Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

350
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
350
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Cancer Survival Analysis01:21

Cancer Survival Analysis

340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant.

JCO global oncology·2026
Same author

Reporting and Outcomes of Brachytherapy for Gynecologic Reirradiation: A Systematic Review.

International journal of radiation oncology, biology, physics·2026
Same author

Bayesian networks as prognostic models in oncology: a systematic review and recommendations for clinical practice.

BMJ oncology·2026
Same author

Corrigendum to "Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer" [Radiother. Oncol. 216 (2026) 111385].

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

A sinGle-arm phase II study to assess efficacy, tOxicity, and quAlity of life following 27Gy in 6 fractions palliative intensity modulated radiotherapy with early integration of palliative care (GOAL27-6).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Detection of errors in organs at risk delineations for radiotherapy for clinical trial reviews.

Physics in medicine and biology·2026

Related Experiment Video

Updated: Jun 21, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K

Are we making progress in curing advanced cervical cancer-again?

Jacob Christian Lindegaard1, Primoz Petric2, Li-Tee Tan3

  • 1Department of Oncology, Aarhus University Hospital, Aarhus, Denmark jacob.lindegaard@auh.rm.dk.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|July 10, 2024
PubMed
Summary

Neoadjuvant chemotherapy may not benefit most cervical cancer patients receiving modern radiotherapy and could be harmful. Further research is needed to identify subgroups who might benefit, especially in resource-limited settings.

Keywords:
BrachytherapyCervical CancerRadiotherapy, Image-GuidedRadiotherapy, Intensity-Modulated

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.8K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

514

Related Experiment Videos

Last Updated: Jun 21, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.8K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

514

Area of Science:

  • Gynecologic Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Definitive treatment for locally advanced cervical cancer has seen radiotherapy advancements, improving outcomes.
  • Chemotherapy progress has lagged, with cisplatin remaining standard for 25 years.
  • The INTERLACE trial suggests survival benefits from neoadjuvant chemotherapy (carboplatin and paclitaxel) before chemoradiation.

Purpose of the Study:

  • To critically evaluate the INTERLACE trial findings in the context of modern radiotherapy and patient selection.
  • To discuss the role of neoadjuvant chemotherapy in locally advanced cervical cancer treatment.
  • To determine if neoadjuvant chemotherapy is necessary for patients treated with advanced radiotherapy techniques.

Main Methods:

  • Review of the INTERLACE trial data and comparison with EMBRACE study outcomes.
  • Analysis of patient selection criteria in INTERLACE and their impact on results.
  • Discussion of modern radiotherapy techniques, including MRI-guided brachytherapy.

Main Results:

  • The standard arm of INTERLACE had inferior survival compared to contemporary state-of-the-art radiotherapy (EMBRACE).
  • INTERLACE patients were younger, healthier, and had less advanced disease, limiting generalizability.
  • Neoadjuvant chemotherapy may not be beneficial for most patients receiving optimal modern radiotherapy and could cause harm.

Conclusions:

  • Neoadjuvant chemotherapy is likely unnecessary for the majority of cervical cancer patients treated with modern definitive radiotherapy.
  • A minor subgroup of patients might benefit from short-course neoadjuvant chemotherapy, requiring identification.
  • Cost-utility analyses are crucial for assessing neoadjuvant chemotherapy's value in low- and middle-income countries with limited radiotherapy access.